EMR cumulative indigenous Measles/Rubella cases counts and surveillance indicators

Between 01/01/2022 and 28/02/2022

| | | Ν | leasles c | ase find | ing repo | rt | | R | ubella (| case fir | nding re | eport | | | | | Indicate | ors: terget | ≥80% | | | | |
|--------------|---|--|---------------------------------|----------------------------|--|------------------|--|---------------------------------------|----------------------------------|----------------------------|---|----------------------|--------------------------|---|---------------------------|-----------------------------------|---|---|--|--|------------|----------------------|--|
| Country | Total suspecte d cases for M/R | Specime ns tested for Measles | Measles lab confirme d | Measle s Epi- Linked | Measles clinicaly compati ble | Total Measles | Measle s discard e d cases | Specimn s tested for Rubella | Rubell a lab confir med | Rubell a Epi- Linked | Rubell a clinica lly comp atable | Total Rubell a | Rubella discarde d | Measles incidenc e/1000,0 00 * | Report ing rate *** | suspects tested for Measles | cases with complet e investig ation | specime ns received at the lab within 5 days | specime ns with adequat e conditio n | results reporte d back within 4 days | | Genotypes reorted | |
| Afghanistan | 1970 | 1970 | 1057 | 0 | 0 | 1057 | 913 | 1381 | 30 | 0 | 0 | 30 | 1351 | 26.53 | 2.29 | 100% | <mark>55%</mark> | 89% | 100% | 80% | 28-02-2022 | | |
| Bahrain | 34 | 34 | 0 | 0 | 0 | 0 | 34 | 34 | 0 | 0 | 0 | 0 | 34 | 0.00 | 1.94 | 100% | 100% | 100% | 100% | 100% | 28-02-2022 | | |
| Djibouti | NR* | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | | | |
| Iran | 625 | 580 | 6 | 0 | 0 | 6 | 619 | 598 | 2 | 0 | 0 | 2 | 596 | 0.07 | 0.73 | 93% | 88% | 94% | | <mark>65%</mark> | 28-02-2022 | | |
| Iraq | 41 | 34 | 0 | 0 | 6 | 6 | 35 | 34 | 1 | 0 | 0 | 1 | 33 | | 0.08 | 83% | 32% | 4% | | | 28-02-2022 | | |
| Jordan | 9 | 9 | 0 | 0 | 0 | 0 | - | 4 | 0 | 0 | 0 | 0 | 4 | 0.00 | 0.09 | 100% | | 100% | 100% | <mark>22%</mark> | 28-02-2022 | | |
| Egypt | 357 | 357 | 0 | 0 | 0 | 0 | 357 | 357 | 0 | 0 | 0 | 0 | 357 | 0.00 | 0.34 | 100% | 93% | 96% | | 100% | 28-02-2022 | | |
| Kuwait | 6 | 6 | 1 | 0 | 0 | 1 | 5 | 6 | 0 | 0 | 0 | 0 | 6 | 0.23 | 0.12 | 100% | 100% | 100% | | 83% | 28-02-2022 | | |
| Lebanon | NR* | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | 31-03-2021 | | |
| Libya | 14 | 12 | 0 | 0 | 0 | 0 | 14 | 12 | 2 | 0 | 0 | 2 | 10 | 0.00 | 0.21 | 86% | | 17% | 100% | <mark>75%</mark> | 28-02-2022 | | |
| Morocco | 5 | 5 | 0 | 0 | 0 | 0 | 5 | 5 | 2 | 0 | 0 | 2 | 3 | | 0.01 | 100% | 80% | | | 100% | 28-02-2022 | | |
| Oman | 60 | 60 | 0 | 0 | 0 | 0 | 60 | 60 | 0 | 0 | 0 | 0 | 60 | 0.00 | 1.15 | 100% | 95% | 92% | | 92% | 28-02-2022 | B3 imp. | |
| Pakistan | 1477 | 1368 | 505 | 17 | 24 | 546 | 931 | 1357 | 43 | 0 | 0 | 43 | 1314 | 2.42 | 0.41 | 93% | 100% | 97% | | <mark>54%</mark> | 31-01-2022 | | |
| Palestine | 6 | 6 | 0 | 0 | 0 | 0 | 6 | 6 | 0 | 0 | 0 | 0 | 6 | 0.00 | 0.11 | 100% | 83% | 100% | 100% | 83% | 28-02-2022 | | |
| Qatar | 24 | 24 | 1 | 0 | 0 | 1 | 23 | 24 | 0 | 0 | 0 | 0 | 24 | 0.34 | 0.78 | 100% | 100% | 67% | | 100% | 28-02-2022 | | |
| Saudi Arabia | 91 | 91 | 14 | 0 | 0 | 14 | 77 | 91 | 6 | 0 | 0 | 6 | 85 | 0.40 | 0.22 | 100% | 99% | 100% | 100% | 100% | 31-01-2022 | | |
| Somalia * | 3822 | 271 | 157 | 0 | 0 | 157 | 3665 | 147 | 0 | 0 | 0 | 0 | 147 | 9.60 | 22.40 | 7% | 99% | 61% | 100% | <mark>47%</mark> | 28-02-2022 | | |
| Sudan | 442 | 319 | 51 | 103 | 0 | 154 | 288 | 135 | 51 | 16 | 0 | 67 | 68 | 3.43 | 0.64 | 72% | 99% | 56% | 100% | <mark>58%</mark> | 28-02-2022 | | |
| Syria | 73 | 73 | 0 | 0 | 0 | 0 | 73 | 73 | 0 | 0 | 0 | 0 | 73 | 0.00 | 0.40 | 100% | 55% | 70% | 100 | 97% | 28-02-2022 | | |
| Tunisia | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 0.00 | 0.01 | 100% | | | | | 28-02-2022 | | |
| UAE | 15 | 15 | 4 | 0 | 1 | 5 | | 15 | 0 | 0 | 0 | 0 | 15 | 0.50 | 0.10 | 100% | 100% | 93% | 100% | 87% | 28-02-2022 | | |
| Yemen | 954 | 914 | 388 | 0 | 8 | 396 | 558 | 914 | 237 | 0 | 74 | 311 | 603 | 12.99 | 1.8301 | 96% | | | 99 | | 28-02-2022 | | |
| Total | 10026 | 6149 | 2184 | 120 | 39 | 2343 | 7683 | 5254 | 374 | 16 | 74 | 464 | 4790 | 2.18 | 1.69 | <mark>61%</mark> | 57% | 59% | <mark>535%</mark> | <mark>59%</mark> | | | |

*The sum of the measles lab confirmed cases +measles epi-linked cases + measles clinically compatible cases/million population

**The sum of the rubella lab confirmed cases +rubella epi-linked cases + rubella clinically compatible cases/million population

***Reporting rate of discarded non-measles non-rubella cases at the national level per 100,000 total

population

****Excluding measles and rubella epi-linked cases

*NR- Not reported

Countries that did not report

* Somalia reported aggregate data

cells=missing data for calculating indicator.

Adequate investigation includes the following data elements:

-District. -Age. -Gender. -Date of rash onset, case notification and investigation -Vaccination status. -Date of last vaccination with MCV -Date specimen collected. -Travel history

| | | | | | | | Between | 01/01/20 | 22 and 28/ | 2/2022 | | | | | | | | | | | | |
|--------------|--|------------------------------|-------------------------------|------------------------------------|-----------------------|--------------------|-----------------------------|---------------------------|---|------------------------------|------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Country | Total Suspected cases for measles | Total specimens tested | Imported Measles cases* | Measles import related* * | Vaccine related*** | Unknow n source | Measles Lab confirmed | Measles Epi- Linked | Measles clinically compati ble | Total confirmed cases# | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
| Afghanistan | 1970 | 1970 | 0 | 0 | 0 | 0 | 1057 | 0 | 0 | 1057 | 580 | 477 | | | | | | | | | | |
| Bahrain | 34 | 34 | 0 | 0 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | | | | | | | | | | |
| Djibouti | NR* | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | | | | | | | | | | |
| Iran | 625 | 580 | 13 | 15 | 20 | 0 | 6 | 0 | 0 | 6 | 3 | 3 | | | | | | | | | | |
| Iraq | 41 | 34 | 0 | 0 | 3 | 0 | 0 | 0 | 6 | 6 | 4 | 2 | | | | | | | | | | |
| Jordan | 9 | 9 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | | | | | | | | | | |
| Egypt | 357 | 357 | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | | | | | | | | | | |
| Kuwait | 6 | 6 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | | | | | | | | | | |
| Lebanon | NR* | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | | | | | | | | | | |
| Libya | 14 | 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | | | | | | | | | | |
| Morocco | 5 | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | | | | | | | | | | |
| Oman | 60 | 60 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | | | | | | | | | | |
| Pakistan | 1477 | 1368 | 0 | 0 | 0 | 0 | 505 | 17 | 24 | 546 | 546 | NR | | | | | | | | | | |
| Palestine | 6 | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | | | | | | | | | | |
| Qatar | 24 | 24 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | | | | | | | | | | |
| Saudi Arabia | 91 | 91 | 0 | 0 | 0 | 0 | 14 | 0 | 0 | 14 | 14 | NR | | | | | | | | | | |
| Somalia | 3822 | 271 | 0 | 0 | 0 | 0 | 157 | 0 | 0 | 157 | 86 | 71 | | | | | | | | | | |
| Sudan | 442 | 319 | 0 | 0 | 0 | 0 | 51 | 103 | 0 | 154 | 121 | 33 | | | | | | | | | | |
| Syria | 73 | 73 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | | | | | | | | | | |
| Tunisia | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | | | | | | | | | | |
| UAE | 15 | 15 | 0 | 0 | 0 | 0 | 4 | 0 | 1 | 5 | 3 | 2 | | | | | | | | | | |
| Yemen | 954 | 914 | 0 | 0 | 0 | 0 | 388 | 0 | 8 | 396 | 203 | 193 | | | | | | | | | | ĺ |
| Total | 10026 | 6149 | 16 | 15 | 30 | 0 | 2184 | 120 | 39 | 2343 | 1562 | 781 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |

Measles final classification and distribution by Month

* Imported measles/rubella case – a case exposed to measles outside the country during the 7-21 days prior to rash onset and supported by epidemiological or virological evidence (for rubella the exposure would be during the 12-23 days prior to rash onset)


** Importation related measles/rubella case – a locally acquired infection occurring as part of a chain of transmission originating from an imported case as supported by epidemiological or virological evidence

***Vaccine related case – a suspect case that has a rash like illness without respiratory symptoms and the rash had onset 7-14 days following vaccination and the lab detected IgM in the blood specimen that was collected 8-56 days after vaccination and there were no secondary cases identified. OR any suspect case from which virus is isolated and genotyping test reveals the virus to be a vaccine strain

Total confirmed cases; include all cases confirmed by laboratory testing or epi linkage, plus those clinical cases that were reported without a laboratory specimen or epi linkage

*NR- Not reported to date

Distribution by final classification of Measles cases in the EMR countries between 01/01/2022 and 28/02/2022



Remark: The boundaries and names shown and the designations used on this map dot not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or area of its frontier or boundaries. Dotted dashed lines on the maps represent approximate border lines for which there may not yet be full agreement.

| | | | | | | | Between | 01/01/202 | 2 and 28/0 | 2/2022 | | | | | | | | | | | | |
|--------------|--|------------------------------|-------------------------------|------------------------------------|-----------------------|--------------------|-----------------------------|---------------------------|---|------------------------------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Country | Total Suspected cases for Rubella | Total specimens tested | Imported Rubella cases* | Rubella import related* * | Vaccine related*** | Unknow n source | Rubella Lab confirmed | Rubella Epi- Linked | Rubella clinically compati ble | Total confirmed cases# | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
| Afghanistan | 1970 | 1381 | 0 | 0 | 0 | 0 | 30 | 0 | 0 | 30 | 18 | 12 | | | | | | | | | | |
| Bahrain | 34 | 34 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | | | | | | | | | | |
| Djibouti | NR* | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | | | | | | | | | | |
| Iran | 625 | 598 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 2 | 0 | 2 | | | | | | | | | | |
| Iraq | 41 | 34 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | | | | | | | | | | |
| Jordan | 9 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | | | | | | | | | | |
| Egypt | 357 | 357 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | | | | | | | | | | |
| Kuwait | 6 | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | | | | | | | | | | |
| Lebanon | NR* | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | | | | | | | | | | |
| Libya | 14 | 12 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 2 | 0 | 2 | | | | | | | | | | |
| Morocco | 5 | 5 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 2 | 0 | 2 | | | | | | | | | | |
| Oman | 60 | 60 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | | | | | | | | | | |
| Pakistan | 1477 | 1357 | 0 | 0 | 0 | 0 | 43 | 0 | 0 | 43 | 43 | NR | | | | | | | | | | |
| Palestine | 6 | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | | | | | | | | | | |
| Qatar | 24 | 24 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | | | | | | | | | | |
| Saudi Arabia | 91 | 91 | 0 | 0 | 0 | 0 | 6 | 0 | 0 | 6 | 6 | NR | | | | | | | | | | |
| Somalia | 3822 | 147 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | | | | | | | | | | |
| Sudan | 442 | 135 | 0 | 0 | 0 | 0 | 51 | 16 | 0 | 67 | 45 | 22 | | | | | | | | | | |
| Syria | 73 | 73 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | | | | | | | | | | |
| Tunisia | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | | | | | | | | | | |
| UAE | 15 | 15 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | | | | | | | | | | |
| Yemen | 954 | 914 | 0 | 0 | 0 | 0 | 237 | 0 | 74 | 311 | 156 | 155 | | | | | | | | | | |
| Total | 10026 | 5254 | 0 | 0 | 0 | 0 | 374 | 16 | 74 | 464 | 269 | 195 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |

Rubella final classification and distribution by Month

* Imported measles/rubella case – a case exposed to measles outside the country during the 7-21 days prior to rash onset and supported by epidemiological or virological evidence (for rubella the exposure would be during the 12-23 days prior to rash onset)


** Importation related measles/rubella case – a locally acquired infection occurring as part of a chain of transmission originating from an imported case as supported by epidemiological or virological evidence

***Vaccine related case – a suspect case that has a rash like illness without respiratory symptoms and the rash had onset 7-14 days following vaccination and the lab detected IgM in the blood specimen that was collected 8-56 days after vaccination and there were no secondary cases identified. OR any suspect case from which virus is isolated and genotyping test reveals the virus to be a vaccine strain

Total confirmed cases; include all cases confirmed by laboratory testing or epi linkage, plus those clinical cases that were reported without a laboratory specimen or epi linkage

*NR- Not reported to date

Distribution by final classification of Rubella cases in the EMR countries between 01/01/2022 and 28/02/2022



Remark: The boundaries and names shown and the designations used on this map dot not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or area of its frontier or boundaries. Dotted dashed lines on the maps represent approximate border lines for which there may not yet be full agreement.

Measles and Rubella laboratory summary report Between 01-Jan-22 and 28-Feb-22

| Country | | | | Meas | les | | | | Rubella | | | | | | | | | | |
|--------------|---------------------|------|----------|------|----------|------|-----------|------|---------|---------------------|------|----------|-----|----------|------|-----------|-----|--|--|
| | specimens tested | % | Positive | % | Negative | % | Equivocal | % | | specimens tested | % | Positive | % | Negative | % | Equivocal | % | | |
| Afghanistan | 1970 | 100% | 1051 | 53% | 910 | 46% | 9 | 0.5% | Γ | 1381 | 70% | 30 | 2% | 1350 | 98% | 1 | 0% | | |
| Bahrain | 34 | 100% | 0 | 0% | 34 | 100% | 0 | 0.0% | | 34 | 100% | 0 | 0% | 34 | 100% | 0 | 0% | | |
| Iran | 580 | 93% | 40 | 7% | 540 | 93% | 0 | 0.0% | | 598 | 96% | 22 | 4% | 576 | 96% | 0 | 0% | | |
| Iraq | 34 | 83% | 1 | 3% | 0 | 0% | 2 | 5.9% | | 34 | 83% | 2 | 6% | 32 | 94% | 0 | 0% | | |
| Jordan | 9 | 100% | 0 | 0% | 9 | 100% | 0 | 0.0% | | 4 | 44% | 0 | 0% | 4 | 100% | 0 | 0% | | |
| Egypt | 357 | 100% | 9 | 3% | 347 | 97% | 1 | 0.3% | | 357 | 100% | 13 | 4% | 344 | 96% | 0 | 0% | | |
| Kuwait | 6 | 100% | 2 | 33% | 4 | 67% | 0 | 0.0% | | 6 | 100% | 0 | 0% | 6 | 100% | 0 | 0% | | |
| Lebanon | NR | NR | NR | NR | NR | NR | NR | NR | | NR | NR | NR | NR | NR | NR | NR | NR | | |
| Libya | 12 | 86% | 0 | 0% | 12 | 100% | 0 | 0.0% | | 12 | 86% | 2 | 17% | 8 | 67% | 2 | 17% | | |
| Morocco | 5 | 100% | 0 | 0% | 5 | 100% | 0 | 0.0% | Г | 5 | 100% | 2 | 40% | 3 | 60% | 0 | 0% | | |
| Oman | 60 | 100% | 7 | 12% | 53 | 88% | 0 | 0.0% | | 60 | 100% | 3 | 5% | 57 | 95% | 0 | 0% | | |
| Pakistan | 1368 | 93% | 505 | 37% | 863 | 63% | 0 | 0.0% | | 1357 | 92% | 43 | 3% | 1314 | 97% | 0 | 0% | | |
| Palestine | 6 | 100% | 0 | 0% | 6 | 100% | 0 | 0.0% | | 6 | 100% | 0 | 0% | 6 | 100% | 0 | 0% | | |
| Qatar | 24 | 100% | 1 | 4% | 23 | 96% | 0 | 0.0% | | 24 | 100% | 0 | 0% | 24 | 100% | 0 | 0% | | |
| Saudi Arabia | 91 | 100% | 14 | 15% | 77 | 85% | 0 | 0.0% | | 91 | 100% | 6 | 7% | 85 | 93% | 0 | 0% | | |
| Somalia | 271 | 7% | 86 | 32% | 185 | 68% | 0 | 0.0% | | 147 | 4% | 0 | 0% | 147 | 100% | 0 | 0% | | |
| Sudan | 319 | 72% | 51 | 16% | 256 | 80% | 12 | 3.8% | | 135 | 31% | 56 | 41% | 74 | 55% | 5 | 4% | | |
| Syria | 73 | 100% | 0 | 0% | 73 | 100% | 0 | 0.0% | Γ | 73 | 100% | 0 | 0% | 73 | 100% | 0 | 0% | | |
| Tunisia | 1 | 100% | 0 | 0% | 1 | 100% | 0 | 0.0% | | 1 | 100% | 0 | 0% | 1 | 100% | 0 | 0% | | |
| UAE | 15 | 100% | 4 | 27% | 10 | 67% | 1 | 6.7% | Γ | 15 | 100% | 0 | 0% | 15 | 100% | 0 | 0% | | |
| Yemen | 914 | 96% | 389 | 43% | 508 | 56% | 17 | 1.9% | | 914 | 96% | 238 | 26% | 529 | 58% | 147 | 16% | | |